Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Neuropathy, hereditary sensory and autonomic, type 1A"
Page 1
AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies.
Trends Mol Med. 2021 Jun;27(6):520-523. doi: 10.1016/j.molmed.2021.02.004. Epub 2021 Mar 10.
Trends Mol Med. 2021.
PMID: 33714697
Free PMC article.
Review.
De novo glycosphingolipid (GSL) biosynthesis defects cause severe neurological diseases, including hereditary sensory and autonomic neuropathy type 1A (HSAN1A), GM3 synthase deficiency, and hereditary spastic paraplegia type …
De novo glycosphingolipid (GSL) biosynthesis defects cause severe neurological diseases, including hereditary sensory and a …
Experimental therapeutics in hereditary neuropathies: the past, the present, and the future.
Herrmann DN.
Herrmann DN.
Neurotherapeutics. 2008 Oct;5(4):507-15. doi: 10.1016/j.nurt.2008.07.001.
Neurotherapeutics. 2008.
PMID: 19019301
Free PMC article.
Review.
Hereditary neuropathies represent approximately 40% of undiagnosed neuropathies in a tertiary clinic setting. ...Some 15% of demyelinating CMT and 70% of axonal CMT await genetic clarification. Other hereditary neuropathies include the heredi …
Hereditary neuropathies represent approximately 40% of undiagnosed neuropathies in a tertiary clinic setting. ...Some 1 …
Item in Clipboard
Cite
Cite